Clinical data: Phase I+IV (domestic)

Phase I clinical results:Follow-up laryngoscopy results after rAD-p53 treatment. Laryngoscopy examination 3 years after rAD-p53 treatment showed that the patient's laryngeal mucosa was smooth and there was no tumor recurrence

Phase II clinical effect:20 patients with head and neck squamous cell carcinoma in the GTRT group. After randomized comparative analysis or self-comparison analysis, rAD-p53 significantly improved the efficacy of radiotherapy in patients with head and neck squamous cell carcinoma

Phase III clinical effect:Disease group: A total of 404 cases of nasopharyngeal carcinoma-300 cases in the GTRT group-104 cases in the RT group. After comparative analysis, it was found that rAD-p53 significantly improved the efficacy of radiotherapy in patients with nasopharyngeal carcinoma

Phase IV clinical effect:After a large amount of data comparative analysis, rAD-p53 significantly improved the efficacy of chemotherapy in patients with extended maxillofacial and oral diseases